A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease
Estimated Enrollment: 160
Actual Study Start Date: October 2015
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)

Study of OTO-104 in Subjects With Unilateral Meniere's Disease
To evaluate the effectiveness of OTO-104 for the treatment of Meniere's Disease.